178 results
Page 2 of 9
6-K
tve7 c73y
7 Nov 23
Report of Foreign Private Issuer
4:30pm
6-K
kshcq
18 Sep 23
Report of Foreign Private Issuer
8:00am
6-K
EX-99.1
q5gwyliz rm8
11 Sep 23
Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results
8:00am
6-K
EX-99.2
ayl8i0okxv86pv4yrr0q
1 Sep 23
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.1
9x4r 0nxu
2 Aug 23
Report of Foreign Private Issuer
8:05am
6-K
EX-99.1
jzwy1spz3amkd v87
31 Jul 23
Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis
8:05am
6-K
EX-99.1
88uix6
26 Jun 23
Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update
8:03am
6-K
EX-99.2
8n7 gwvggr
16 Jun 23
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.1
nw8a0dmviu5k64g4
31 May 23
Report of Foreign Private Issuer
8:09am
6-K
EX-99.1
uz8d 2bo3a2w6
8 May 23
Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to
8:02am
6-K
EX-99.1
egphoi7oi6ko13
19 Apr 23
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapy
8:03am
6-K
EX-99.1
9az2tb4 m2
17 Apr 23
Enlivex Appoints Andrew Singer to its Board of Directors
8:03am
6-K
EX-99.1
ou8wjx6i6zsf
4 Apr 23
Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates
8:05am
6-K
EX-99.1
ewajbue3xe
3 Apr 23
Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid Tumors
8:05am
6-K
EX-99.1
2xwe6vngw
31 Mar 23
Report of Foreign Private Issuer
4:30pm
6-K
EX-10.1
9of3eao bgg
30 Dec 22
Report of Foreign Private Issuer
4:02pm
424B5
cp2t700fu6gk
30 Dec 22
Prospectus supplement for primary offering
4:01pm
6-K
EX-99.1
sua1qxtof0lx
5 Dec 22
Enlivex Announces Third Quarter 2022 Financial Results and Provides a Business Update
8:05am
6-K
EX-99.2
lwpqieyxc
2 Dec 22
Condensed Consolidated Financial Statements
4:15pm